Trial Profile
Single-Dose Study to Compare the Pharmacokinetics, Safety, and Tolerability of Three Formulations of Infliximab (CT-P13, EU-sourced Infliximab and US-sourced Infliximab) in Healthy Volunteers
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 11 May 2015
Price :
$35
*
At a glance
- Drugs Infliximab (Primary)
- Indications Ankylosing spondylitis; Plaque psoriasis; Psoriatic arthritis; Rheumatoid arthritis; Ulcerative colitis
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Celltrion
- 11 May 2015 Pharmacokinetic bioequivalence following single dose administration Primary endpoint considered met.
- 11 May 2015 New trial record